158 related articles for article (PubMed ID: 33773557)
1. The Proteomics and Metabolomics Analysis for Screening the Molecular Targets of Action of β-Eudesmol in Cholangiocarcinoma.
Kotawong K; Chajaroenkul W; Roytrakul S; Phaonakrop N; Na-Bangchang K
Asian Pac J Cancer Prev; 2021 Mar; 22(3):909-918. PubMed ID: 33773557
[TBL] [Abstract][Full Text] [Related]
2. Proteomics Analysis for Identification of Potential Cell Signaling Pathways and Protein Targets of Actions of Atractylodin and β-Eudesmol Against Cholangiocarcinoma.
Kotawong K; Chaijaroenkul W; Roytrakul S; Phaonakrop N; Na-Bangchang K
Asian Pac J Cancer Prev; 2020 Mar; 21(3):621-628. PubMed ID: 32212786
[TBL] [Abstract][Full Text] [Related]
3. Screening of Molecular Targets of Action of Atractylodin in Cholangiocarcinoma by Applying Proteomic and Metabolomic Approaches.
Kotawong K; Chaijaroenkul W; Roytrakul S; Phaonakrop N; Na-Bangchang K
Metabolites; 2019 Nov; 9(11):. PubMed ID: 31683902
[TBL] [Abstract][Full Text] [Related]
4. Effect of β-Eudesmol on NQO1 suppression-enhanced sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Srijiwangsa P; Ponnikorn S; Na-Bangchang K
BMC Pharmacol Toxicol; 2018 Jun; 19(1):32. PubMed ID: 29914576
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory effect of β-eudesmol on cholangiocarcinoma cells and its potential suppressive effect on heme oxygenase-1 production, STAT1/3 activation, and NF-κB downregulation.
Mathema VB; Chaijaroenkul W; Karbwang J; Na-Bangchang K
Clin Exp Pharmacol Physiol; 2017 Nov; 44(11):1145-1154. PubMed ID: 28732110
[TBL] [Abstract][Full Text] [Related]
6. Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway.
Vanaroj P; Chaijaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2023 Feb; 24(2):551-558. PubMed ID: 36853304
[TBL] [Abstract][Full Text] [Related]
7. β-Eudesmol Inhibits the Migration of Cholangiocarcinoma Cells by Suppressing Epithelial-Mesenchymal Transition via PI3K/AKT and p38MAPK Modulation.
Acharya B; Chajaroenkul W; Na-Bangchang K
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2573-2581. PubMed ID: 36037109
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic activities and effects of atractylodin and β-eudesmol on the cell cycle arrest and apoptosis on cholangiocarcinoma cell line.
Kotawong K; Chaijaroenkul W; Muhamad P; Na-Bangchang K
J Pharmacol Sci; 2018 Feb; 136(2):51-56. PubMed ID: 29525035
[TBL] [Abstract][Full Text] [Related]
9. A randomized placebo-controlled phase I clinical trial to evaluate the immunomodulatory activities of Atractylodes lancea (Thunb) DC. in healthy Thai subjects.
Kulma I; Panrit L; Plengsuriyakarn T; Chaijaroenkul W; Warathumpitak S; Na-Bangchang K
BMC Complement Med Ther; 2021 Feb; 21(1):61. PubMed ID: 33579265
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of β-eudesmol in human cholangiocarcinoma xenografted nude mouse model.
Plengsuriyakarn T; Karbwang J; Na-Bangchang K
Clin Exp Pharmacol Physiol; 2015 Mar; 42(3):293-304. PubMed ID: 25545782
[TBL] [Abstract][Full Text] [Related]
11. Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Dokduang H; Juntana S; Techasen A; Namwat N; Yongvanit P; Khuntikeo N; Riggins GJ; Loilome W
Tumour Biol; 2013 Dec; 34(6):3519-28. PubMed ID: 23812726
[TBL] [Abstract][Full Text] [Related]
12. Suppression of Cholangiocarcinoma Cell Growth and Proliferation by Atractylodes lancea (Thunb) DC. through ERK-Signaling Cascade.
Martviset P; Panrit L; Chantree P; Muhamad P; Na-Bangchang K
Asian Pac J Cancer Prev; 2021 Nov; 22(11):3633-3640. PubMed ID: 34837922
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential and pharmacological activities of β-eudesmol.
Acharya B; Chaijaroenkul W; Na-Bangchang K
Chem Biol Drug Des; 2021 Apr; 97(4):984-996. PubMed ID: 33449412
[TBL] [Abstract][Full Text] [Related]
15. TCF21 inhibits tumor-associated angiogenesis and suppresses the growth of cholangiocarcinoma by targeting PI3K/Akt and ERK signaling.
Duan HX; Li BW; Zhuang X; Wang LT; Cao Q; Tan LH; Qu GF; Xiao S
Am J Physiol Gastrointest Liver Physiol; 2019 Jun; 316(6):G763-G773. PubMed ID: 30920845
[TBL] [Abstract][Full Text] [Related]
16. Stathmin decreases cholangiocarcinoma cell line sensitivity to staurosporine-triggered apoptosis via the induction of ERK and Akt signaling.
Wang Y; Gao Z; Zhang D; Bo X; Wang Y; Wang J; Shen S; Liu H; Suo T; Pan H; Ai Z; Liu H
Oncotarget; 2017 Feb; 8(9):15775-15788. PubMed ID: 28178656
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
18. β-Eudesmol induces JNK-dependent apoptosis through the mitochondrial pathway in HL60 cells.
Li Y; Li T; Miao C; Li J; Xiao W; Ma E
Phytother Res; 2013 Mar; 27(3):338-43. PubMed ID: 22585533
[TBL] [Abstract][Full Text] [Related]
19. Tip60 Suppresses Cholangiocarcinoma Proliferation and Metastasis via PI3k-AKT.
Zhang Y; Ji G; Han S; Shao Z; Lu Z; Huo L; Zhang J; Yang R; Feng Q; Shen H; Wang H; Li X
Cell Physiol Biochem; 2018; 50(2):612-628. PubMed ID: 30308494
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of heritability of β-eudesmol/hinesol content ratio in Atractylodes lancea De Candolle.
Tsusaka T; Makino B; Ohsawa R; Ezura H
Hereditas; 2020 Mar; 157(1):7. PubMed ID: 32160928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
